Acumen Pharma says ALTITUDE-AD missed endpoints; to cease sabirnetug development, explore strategic options

Acumen Pharma said its ALTITUDE-AD study of sabirnetug in Alzheimer's disease missed primary and key secondary endpoints. The company will cease clinical development of sabirnetug, preserve cash and explore strategic options.

Detected & updated continuously · Source: Nebula